Current approach to safe osteoarthritis pharmacotherapy

Gurkirpal Singh; Matthew D. Heller; David Silver; Peter T. Singleton; Eugene P. Toomey; George Triadafilopoulos

Current approach to safe osteoarthritis pharmacotherapy

Gurkirpal Singh, Matthew D. Heller, David Silver, Peter T. Singleton, Eugene P. Toomey, George Triadafilopoulos

Research output: Contribution to journal › Review article › peer-review

Abstract

Perhaps the most frequent decision that clinicians face on a daily basis in treating patients with osteoarthritis (OA) is which nonsteroidal anti-inflammatory drug (NSAID) to use for an individual patient. Such a decision needs to take into account a patient's risk of gastric toxicities and any comorbid conditions the patient may have. A current approach leading to development of a treatment algorithm that specifically focuses on identifying and ameliorating gastrointestinal and cardiovascular side effect risks sometimes associated with NSAID therapy is presented here to guide the selection of appropriate pharmacotherapy in the management of OA.

Original language	English (US)
Pages (from-to)	3-16
Number of pages	14
Journal	Consultant
Volume	43
Issue number	8 SUPPL.
State	Published - Jul 2003
Externally published	Yes

Keywords

Cardiovascular risk
COX-2 inhibition
Gastric toxicities
NSAIDs
Osteoarthritis
Proton pump inhibitors

ASJC Scopus subject areas

General Medicine

Cite this

@article{e62ef356794049759db68be5af329a20,

title = "Current approach to safe osteoarthritis pharmacotherapy",

abstract = "Perhaps the most frequent decision that clinicians face on a daily basis in treating patients with osteoarthritis (OA) is which nonsteroidal anti-inflammatory drug (NSAID) to use for an individual patient. Such a decision needs to take into account a patient's risk of gastric toxicities and any comorbid conditions the patient may have. A current approach leading to development of a treatment algorithm that specifically focuses on identifying and ameliorating gastrointestinal and cardiovascular side effect risks sometimes associated with NSAID therapy is presented here to guide the selection of appropriate pharmacotherapy in the management of OA.",

keywords = "Cardiovascular risk, COX-2 inhibition, Gastric toxicities, NSAIDs, Osteoarthritis, Proton pump inhibitors",

author = "Gurkirpal Singh and Heller, {Matthew D.} and David Silver and Singleton, {Peter T.} and Toomey, {Eugene P.} and George Triadafilopoulos",

year = "2003",

month = jul,

language = "English (US)",

volume = "43",

pages = "3--16",

journal = "Consultant",

issn = "0010-7069",

publisher = "Cliggott Publishing Co.",

number = "8 SUPPL.",

}

TY - JOUR

T1 - Current approach to safe osteoarthritis pharmacotherapy

AU - Singh, Gurkirpal

AU - Heller, Matthew D.

AU - Silver, David

AU - Singleton, Peter T.

AU - Toomey, Eugene P.

AU - Triadafilopoulos, George

PY - 2003/7

Y1 - 2003/7

N2 - Perhaps the most frequent decision that clinicians face on a daily basis in treating patients with osteoarthritis (OA) is which nonsteroidal anti-inflammatory drug (NSAID) to use for an individual patient. Such a decision needs to take into account a patient's risk of gastric toxicities and any comorbid conditions the patient may have. A current approach leading to development of a treatment algorithm that specifically focuses on identifying and ameliorating gastrointestinal and cardiovascular side effect risks sometimes associated with NSAID therapy is presented here to guide the selection of appropriate pharmacotherapy in the management of OA.

AB - Perhaps the most frequent decision that clinicians face on a daily basis in treating patients with osteoarthritis (OA) is which nonsteroidal anti-inflammatory drug (NSAID) to use for an individual patient. Such a decision needs to take into account a patient's risk of gastric toxicities and any comorbid conditions the patient may have. A current approach leading to development of a treatment algorithm that specifically focuses on identifying and ameliorating gastrointestinal and cardiovascular side effect risks sometimes associated with NSAID therapy is presented here to guide the selection of appropriate pharmacotherapy in the management of OA.

KW - Cardiovascular risk

KW - COX-2 inhibition

KW - Gastric toxicities

KW - NSAIDs

KW - Osteoarthritis

KW - Proton pump inhibitors

UR - http://www.scopus.com/inward/record.url?scp=0042171870&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042171870&partnerID=8YFLogxK

M3 - Review article

AN - SCOPUS:0042171870

SN - 0010-7069

VL - 43

SP - 3

EP - 16

JO - Consultant

JF - Consultant

IS - 8 SUPPL.

ER -

Current approach to safe osteoarthritis pharmacotherapy

Abstract

Keywords

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this